Randomized  Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative

References

• Fanaroff AC, Califf RM, Harrington RA, Granger CB, McMurray JJV, Patel MR, et al. Randomized trials versus common sense and clinical observation: JACC review topic of the week. J Am Coll Cardiol. 2020;76(5):580–9.
   PubMed Web of Science ®Google Scholar
• Korn EL, Freidlin B. Methodology for comparative effectiveness research: potential and limitations. J Clin Oncol. 2012;30(34):4185–7. doi:10.1200/JCO.2012.44.8233.
   PubMed Web of Science ®Google Scholar
• Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674–8. doi:10.1056/NEJMsb1901642.
   PubMed Web of Science ®Google Scholar
• Bansal A, Sullivan SD, Hershman DL, Lyman GH, Barlow WE, McCune JS, et al. A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. J Comp Eff Res. 2017;6(5):461–70. doi:10.2217/cer-2017-0005.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Comparative effectiveness research in oncology: the need for clarity, transparency and vision. Cancer Invest. 2009;27(6):593–7. doi:10.1080/07357900903109952.
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Levit LA, Raghavan D, Hudis CA, Wong S, Dueck A, et al. Untapped potential of observational research to inform clinical decision making: American Society of Clinical Oncology Research Statement. J Clin Oncol. 2017;35(16):1845–54. : doi:10.1200/JCO.2017.72.6414.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7. doi:10.1182/blood-2007-10-116327.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117(9):1917–27. doi:10.1002/cncr.25691.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Poniewierski MS, Culakova E, Lyman GH, Khorana AA, Pabinger I, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a Global Prospective Study (CANTARISK. The Oncol. 2018;23(2):247–55.
   PubMed Web of Science ®Google Scholar
• Shayne M, Culakova E, Poniewierski MS, Dale DC, Crawford J, Wogu AF, et al. Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies. J Geriatr Oncol. 2013;4(4):310–8.
   PubMed Web of Science ®Google Scholar
• Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3(2):434–44. doi:10.1002/cam4.200.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S, et al. Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? Cancer Med. 2015;4(8):1153–60. doi:10.1002/cam4.454.
   PubMed Web of Science ®Google Scholar
• Caterino JM, Adler D, Durham DD, Yeung S-CJ, Hudson MF, Bastani A, et al. Analysis of diagnoses, symptoms, medications, and admissions among patients with cancer presenting to emergency departments. JAMA Netw Open. 2019;2(3):e190979. doi:10.1001/jamanetworkopen.2019.0979.
   PubMed Web of Science ®Google Scholar
• Chen S-S, Tang S-C, Li K, et al. Predicting the survival of triple-negative breast cancer in different stages: a SEER Population Based Research Referring to Clinicopathological Factors. Cancer Invest Accepted author version poster online 19 Oct 2020, 2020.
   Google Scholar
• Zhu Z, Zhong F. Comparative analysis of outcomes and clinicopathological characteristics of duodenal adenocarcinoma: a SEER Analysis. Cancer Invest Accepted author version posted online 19 Oct 2020, 2020.
   Google Scholar
• Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among medicare beneficiaries with early-stage breast cancer, 2005–2009. JAMA Oncol. 2015;1(8):1098–109. doi:10.1001/jamaoncol.2015.2722.
   PubMed Web of Science ®Google Scholar
• Rajan SS, Lyman GH, Stearns SC, et al. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care. 2011;49:649–57.
   PubMed Web of Science ®Google Scholar
• Sanfilippo KM, Luo S, Wang T-F, Fiala M, Schoen M, Wildes TM, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94(11):1176–84.
   PubMed Web of Science ®Google Scholar
• Li A, Wu Q, Warnick G, Li S, Libby EN, Garcia DA, et al. The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. Ann Hematol. 2020;99(1):121–6.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Henk HJ. Association of generic imatinib availability and pricing with trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia. JAMA Oncol. 2020:e204660. doi:10.1001/jamaoncol.2020.4660. Cited in PubMed; PMID: 33001149.
   PubMed Web of Science ®Google Scholar
• Panattoni L, Fedorenko C, Greenwood-Hickman MA, Kreizenbeck K, Walker JR, Martins R, et al. Characterizing potentially preventable cancer- and chronic disease-related emergency department use in the year after treatment initiation: a regional study. J Oncol Pract. 2018;14(3):e176–e185. doi:10.1200/JOP.2017.028191.
   PubMed Web of Science ®Google Scholar
• Agiro A, Ma Q, Acheson AK, Wu S-J, Patt DA, Barron JJ, et al. Risk of neutropenia-related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer. J Clin Oncol. 2016;34(32):3872–9. doi:10.1200/JCO.2016.67.2899.
   PubMed Web of Science ®Google Scholar
• Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, Van Le L, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013;129(1):74–80.
   PubMed Web of Science ®Google Scholar
• Pawloski PA, Thomas AJ, Kane S, Vazquez-Benitez G, Shapiro GR, Lyman GH, et al. Predicting neutropenia risk in patients with cancer using electronic data. J Am Med Inform Assoc. 2017;24(e1):e129–e135. doi:10.1093/jamia/ocw131.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, COVID-19 and Cancer Consortium, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–18. doi:10.1016/S0140-6736(20)31187-9.
   PubMed Web of Science ®Google Scholar
• Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw. 2015;13(11):1383–93.
   PubMed Web of Science ®Google Scholar
• Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, et al. Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020;126(6):1208–16. doi:10.1002/cncr.32645.
   PubMed Web of Science ®Google Scholar
• Frieden TR. Evidence for health decision making – beyond randomized, controlled trials. N Engl J Med. 2017;377:465–75. doi:10.1056/NEJMra1614394.
   PubMed Web of Science ®Google Scholar
• Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16(5):312–25. doi:10.1038/s41571-019-0167-7.
   PubMed Web of Science ®Google Scholar
• Desai A, Warner J, Kuderer N, Thompson M, Painter C, Lyman G, et al. Crowdsourcing a crisis response for COVID-19 in oncology. Nat Cancer. 2020;1(5):473–4.
   Google Scholar
• Desai A, Kuderer NM, Lyman GH. Crowdsourcing in crisis: rising to the occasion. JCO Clin Cancer Inform. 2020;4:551–4. doi:10.1200/CCI.20.00054.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Lyman GH. COVID-19, cancer, and consequences: where are we now? Cancer Invest. 2020;38(8-9):431–435.
   PubMed Web of Science ®Google Scholar
• Califf RM, Hernandez AF, Landray M. Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomized harmony. JAMA. 2020;324(7):625.
   PubMed Web of Science ®Google Scholar
• Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu C-Y, et al. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discov. 2020;10(10):1514–27. doi:10.1158/2159-8290.CD-20-0941.
   PubMed Web of Science ®Google Scholar